TABLE 2.
Results from retesting of end-of-treatment and end-of-follow-up plasma samples by TMA (VERSANT HCV RNA Qualitative Assay)
| Patient category (n)a | No. of patients who were
|
|||
|---|---|---|---|---|
| HCV RNA positive by TMA at:
|
HCV RNA negative by TMA
|
|||
| ETRb | EFUb | ETR | EFU | |
| Sustained responders (78) | 3 | 0 | 75 | 78 |
| Relapse patients (60) | 4 | 60 | 56 | 0 |
| Nonresponders (39) | 39 | 39 | 0 | 0 |
a
Virologic response of patients is defined according to the results of RT-PCR (Cobas Amplicor HCV version 2.0).
b
ETR, end of treatment (week 48); EFU, end of follow-up (week 72).